Watch for an announcement about the 2024 HTRS/Spark Therapeutics Mentored Research Award in spring 2024.
Join HTRS today to receive all our award announcements! HTRS Trainee-level memberships are complimentary for the duration of your training.
The HTRS/Spark MRA for Gene Therapy in Hemophilia A provides funding for MDs, PhDs, and/or a collaboration between two applicants (e.g. one MD and one PhD) carrying out mentored research for Gene Therapy in Hemophilia A. Fellows or junior attendings/junior faculty (MDs, PhD postdocs, DOs, MBBSs or the equivalent) pursuing careers in clinical, translational, or basic science research – specifically for Gene Therapy in Hemophilia A – are encouraged to apply.
HTRS encourages applicants from historically excluded and underrepresented populations to apply, understanding that a diverse scientific workforce will, according to NIH research: foster scientific innovation, contribute to robust learning environments, improve the quality of the research, and advance the likelihood that underserved or health-disparate populations will benefit from this research. This includes individuals from racial and ethnic groups who have been shown by the National Science Foundation to be underrepresented and/or historically excluded in health-related sciences on a national basis, as well as individuals with disabilities, students from low socioeconomic (SES) status backgrounds, individuals from disadvantaged backgrounds, and women. HTRS bases our diversity policy on the Notice of NIH’s Interest in Diversity.
Seema Patel, PhD Emory University Supported by an independent medical training grant from Spark Therapeutics.